<DOC>
	<DOCNO>NCT00148369</DOCNO>
	<brief_summary>The primary purpose study evaluate clinical serologic outcome discontinuation liatermin therapy assess development new clinical condition beyond expect patient advance Parkinson 's disease . In addition , development resolution anti-r-metHuGDNF binding neutralize antibody monitor .</brief_summary>
	<brief_title>A Multi-Center , Observational Safety Registry Subjects With Idiopathic Parkinson 's Disease Previously Treated With Intraputaminal Infusion Liatermin</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Subjects must diagnosis bilateral , idiopathic Parkinson 's Disease enrol treated intraputaminal infusion liatermin previous Amgen/Medtronicsponsored trial ( protocols 20010109 20030160 ) Bristol openlabel study At time implant ( Study 20030168 ) , subject need 35 70 year age</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>